Navigation Links
Copaxone Treatment over Two Years after Short Term Induction with,Mitoxantrone Provided Sustained Benefits to Active,Relapsing-Remitting Multiple Sclerosis Patients

onal pharmaceutical products, the introduction of competing generic equivalents, the extent to which Teva may obtain U.S. market exclusivity for certain of its new generic products and regulatory changes that may prevent Teva from utilizing exclusivity periods, competition from brand-name companies that are under increased pressure to counter generic products, or competitors that seek to delay the introduction of generic products, the impact of consolidation of our distributors and customers, potential liability for sales of generic products prior to a final resolution of outstanding patent litigation, including that relating to the generic versions of Allegra(R) and Neurontin(R), the effects of competition on our innovative products, especially Copaxone(R) sales, the impact of pharmaceutical industry regulation and pending legislation that could affect the pharmaceutical industry, the difficulty of predicting U.S. Food and Drug Administration, European Medicines Agency and other regulatory authority approvals, the regulatory environment and changes in the health policies and structures of various countries, our ability to achieve expected results though our innovative R&D efforts, Teva's ability to successfully identify, consummate and integrate acquisitions, potential exposure to product liability claims to the extent not covered by insurance, dependence on the effectiveness of our patents and other protections for innovative products, significant operations worldwide that may be adversely affected by terrorism, political or economical instability or major hostilities, supply interruptions or delays that could result from the complex manufacturing of our products and our global supply chain, environmental risks, fluctuations in currency, exchange and interest rates, and other factors that are discussed in Teva's Annual Report on Form 20-F and its other filings with the U.S. Securities and Exchange Commission. Forward-looking statements speak only as of the dat
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Treatment with Copaxone Plus Minocycline Showed Substantial Reduction of Disease Activity in Patients with Active Relapsing-Remitting Multiple Sclerosis
2. Treatment with Copaxone Plus Minocycline Showed Substantial Reduction of Disease Activity in Patients with Active Relapsing-Remitting Multiple Sclerosis
3. Data on Higher Dose of Copaxone and Data Showing Copaxone is Most Cost Effective
4. Data Published in Neurology Showed That Higher Dose of Copaxone Increased Efficacy in Relapsing-Remitting Multiple Sclerosis (RRMS)
5. First Pharmacoeconomic Analysis with Long-Term Data Showed Copaxone Was More Cost-Effective Than Interferon Beta Therapies for Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)
6. Point of Care Strep Tests Speed Treatment, Lower Costs
7. Rapid HIV Testing Increases Possibility of Treatment
8. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
9. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
Post Your Comments:
(Date:9/18/2014)... 2014  Spring Bank Pharmaceuticals, Inc., a clinical-stage ... of RNA viruses, today announced a research collaboration ... animal testing of the Company,s lead compound, SB ... Pathogens," against which currently there are no effective ... Bank,s proprietary Small Molecule Nucleic Acid Hybrid ...
(Date:9/18/2014)... 18, 2014 /CNW/ - A new expert panel report, ... , released today by the Council of Canadian ... medicines for children. Each year about half of ... least one prescription drug. Much of this prescribing is ... use), creating potential health risks. Children have ...
(Date:9/18/2014)... , Sept. 18, 2014   Auxilium Pharmaceuticals, ... specialty biopharmaceutical company, today announced the first presentation ... AUX-CC-867 MULTICORD (MULtiple Treatment Investigation of Collagenase Optimizing ... study evaluated collagenase clostridium histolyticum (CCH) for the ... same hand. In addition, the study examined expanded ...
Breaking Medicine Technology:Spring Bank Pharmaceuticals Announces NIH Collaboration for Testing of SB 9200 Against Multiple Viral Pathogens 2Studying medicines in children is always possible and is in their best interest, finds Expert Panel 2Studying medicines in children is always possible and is in their best interest, finds Expert Panel 3Auxilium Pharmaceuticals, Inc. Presents XIAFLEX (CCH) Data From MULTICORD And Retreatment Studies At The ASSH Annual Meeting 2Auxilium Pharmaceuticals, Inc. Presents XIAFLEX (CCH) Data From MULTICORD And Retreatment Studies At The ASSH Annual Meeting 3Auxilium Pharmaceuticals, Inc. Presents XIAFLEX (CCH) Data From MULTICORD And Retreatment Studies At The ASSH Annual Meeting 4Auxilium Pharmaceuticals, Inc. Presents XIAFLEX (CCH) Data From MULTICORD And Retreatment Studies At The ASSH Annual Meeting 5Auxilium Pharmaceuticals, Inc. Presents XIAFLEX (CCH) Data From MULTICORD And Retreatment Studies At The ASSH Annual Meeting 6Auxilium Pharmaceuticals, Inc. Presents XIAFLEX (CCH) Data From MULTICORD And Retreatment Studies At The ASSH Annual Meeting 7
... Incorporated,s (Nasdaq: VPHM ) first quarter financial results ... 28, 2011 before the open of the U.S. financial markets. ... live audio webcast at 9:00 a.m. Eastern Time on the ... the 2011 first quarter financial results and other business. ...
... LLC, through its website lawsuitssettlementfunding.com announced today ... in need of lawsuit cash advances ... leader; however they are striving to set themselves apart ... that they have ramped up their operations involving Avandia ...
Cached Medicine Technology:ViroPharma to Release 2011 First Quarter Financial Results On April 28, 2011 2Legal-Bay LLC Announces Opening of Jones Act Lawsuit Funding Division 2
(Date:9/18/2014)... HealthDay Reporter , THURSDAY, Sept. 18, 2014 ... West Africa is starting to spread faster than ever, the World ... the deadly viral infection were reported in just one week. ... with roughly half of those reported in the past three weeks, ... tops 2,600. WHO has estimated that as many as 20,000 ...
(Date:9/18/2014)... It’s been just a few short weeks ... bunion splint to website visitors, but already the response has ... absolutely delighted. It is perfect and I find it sooo ... THANK YOU FOR LISTENING!!!" Another user compared the original ... used to slip to the end of my toe. Now ...
(Date:9/18/2014)... It is that time of year – time ... again, Evensong Spa at Heidel House Resort ... at a special $50 rate Oct. 20 through Nov. 1. ... & Resorts , is the only Wisconsin destination spa participating ... health and wellness by experiencing affordable spa and wellness treatments. ...
(Date:9/18/2014)... supplements of selenium or vitamin E don,t seem ... men, a new study indicates. Previous animal research ... cataracts. To investigate this further, William Christen, from Brigham ... and his colleagues examined data from a randomized, placebo-controlled ... initially designed to study prevention of prostate cancer. ...
(Date:9/18/2014)... 19, 2014 In 2003, ... Mission (Misión Barrio Adentro), which it hoped ... system (see Section 6.1.3.). In 2009, it ... Autonomous Service of Pharmaceutical Elaborations (Servicio Autónomo ... provides medicines at a cheaper rate than ...
Breaking Medicine News(10 mins):Health News:New Ebola Cases Top 700 in Just One Week, Officials Report 2Health News:New Ebola Cases Top 700 in Just One Week, Officials Report 3Health News:Feedback for the New Bunion Bootie Design Feedback is Already Pouring In, and Bunion Sufferers Love It 2Health News:Feedback for the New Bunion Bootie Design Feedback is Already Pouring In, and Bunion Sufferers Love It 3Health News:Evensong Spa Celebrates Spa Week with $50 Services 2Health News:Evensong Spa Celebrates Spa Week with $50 Services 3Health News:Vitamin E, Selenium Supplements Don't Seem to Prevent Cataracts 2Health News:Venezuela Pharmaceutical Market worth $22.2 billion with 12% CAGR by 2020 Says a New Report Available at MarketOptimizer.org 2Health News:Venezuela Pharmaceutical Market worth $22.2 billion with 12% CAGR by 2020 Says a New Report Available at MarketOptimizer.org 3Health News:Venezuela Pharmaceutical Market worth $22.2 billion with 12% CAGR by 2020 Says a New Report Available at MarketOptimizer.org 4
... By Randy Dotinga HealthDay Reporter , TUESDAY, Sept. ... gel based on the active ingredient of the injectable Botox ... known as crow,s feet -- without the pain of needles. ... toxin, last for about four months, comparable to that produced ...
... HealthDay Reporter , TUESDAY, Sept. 20 (HealthDay News) -- Young adults ... birth much thought, but a new study finds that health problems ... some time. From 18 to 36 years of age, people ... death compared to young adults born at a normal gestational age, ...
... Reporter , TUESDAY, Sept. 20 (HealthDay News) -- Adding ... and teens with obsessive-compulsive disorder, new research shows. ... the Journal of the American Medical Association , ... obsessive-compulsive disorder (OCD). "[If] a child has ...
... against methamphetamine and nicotine have been selected to receive ... The two scientists, Dr. Thomas Kosten, of Baylor ... the University of Connecticut, Storrs, will each receive $500,000 ... according to the National Institute on Drug Abuse (NIDA), ...
... 20 (HealthDay News) -- New research finds that compared to ... diagnosis and boosted the likelihood that high-risk, underserved women who ... But there,s a big catch. Researchers were able to reduce ... -- compared to the usual $3,500 -- thanks to a ...
... of Health (NIH) has awarded nearly $2 million to ... University to develop a new class of therapeutics for ... five-year project focuses on developing biomaterials capable of capturing ... to wound sites to enhance tissue regeneration in adults. ...
Cached Medicine News:Health News:Anti-Wrinkle Gel Might Work Like Botox Without Needles 2Health News:Anti-Wrinkle Gel Might Work Like Botox Without Needles 3Health News:Problems From Preterm Birth May Return in Adulthood 2Health News:Problems From Preterm Birth May Return in Adulthood 3Health News:Adding Psychotherapy to Meds Helps Kids With OCD 2Health News:NIDA Avant-Garde-Medications Development Award winners announced 2Health News:MRI Can Spot Breast Cancer in High-Risk Women: Study 2Health News:Transformative NIH grant will support development of tissue regeneration therapeutics 2Health News:Transformative NIH grant will support development of tissue regeneration therapeutics 3
Substrate Plasma for Factor V Assay by STA© Analyzers. Freeze-dried human plasma, artificially depleted of factor V....
Substrate Plasma for Factor VIII Assay by STA© Analyzers. Freeze-dried human plasma from which factor VIII has been removed by selective immuno-adsorption....
Immuno-turbidimetric Assay of von Willebrand Factor (vWF) Antigen by STA© Analyzers. Microlatex particles coated with rabbit anti-human vWF antibodies....
Colorimetric Assay of Plasminogen Activity by STA© Analyzers....
Medicine Products: